NO993982L - Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes - Google Patents

Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes

Info

Publication number
NO993982L
NO993982L NO993982A NO993982A NO993982L NO 993982 L NO993982 L NO 993982L NO 993982 A NO993982 A NO 993982A NO 993982 A NO993982 A NO 993982A NO 993982 L NO993982 L NO 993982L
Authority
NO
Norway
Prior art keywords
glitazone
sulfonylurea
synergistic
diabetes
combinations
Prior art date
Application number
NO993982A
Other languages
English (en)
Norwegian (no)
Other versions
NO993982D0 (no
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO993982D0 publication Critical patent/NO993982D0/no
Publication of NO993982L publication Critical patent/NO993982L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO993982A 1997-02-19 1999-08-18 Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes NO993982L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
NO993982D0 NO993982D0 (no) 1999-08-18
NO993982L true NO993982L (no) 1999-08-18

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993982A NO993982L (no) 1997-02-19 1999-08-18 Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes

Country Status (29)

Country Link
US (2) US5859037A (enExample)
EP (1) EP0957923A1 (enExample)
JP (1) JP2001512478A (enExample)
KR (1) KR20000071179A (enExample)
CN (1) CN1244801A (enExample)
AR (1) AR011829A1 (enExample)
AU (1) AU741215B2 (enExample)
BG (1) BG103671A (enExample)
BR (1) BR9714505A (enExample)
CA (1) CA2272478A1 (enExample)
CZ (1) CZ289299A3 (enExample)
EA (1) EA199900725A1 (enExample)
EE (1) EE9900345A (enExample)
GT (1) GT199800037A (enExample)
HN (1) HN1997000167A (enExample)
HU (1) HUP0001528A3 (enExample)
IL (1) IL130027A (enExample)
IS (1) IS5058A (enExample)
NO (1) NO993982L (enExample)
NZ (1) NZ336002A (enExample)
PA (1) PA8447401A1 (enExample)
PE (1) PE74399A1 (enExample)
PL (1) PL335166A1 (enExample)
SK (1) SK111899A3 (enExample)
SV (1) SV1998000010A (enExample)
TR (1) TR199902033T2 (enExample)
UY (1) UY24893A1 (enExample)
WO (1) WO1998036755A1 (enExample)
ZA (1) ZA981343B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
EP1787646A3 (en) * 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
KR20010013840A (ko) * 1997-06-18 2001-02-26 피터 기딩스 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
CA2354053A1 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
CA2367955C (en) * 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
TR200401145T4 (tr) 2000-04-13 2004-07-21 Pfizer Products Inc. Gliburit ve milrinonun sinerjistik etkisi.
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CN100544717C (zh) 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
ES2556244T3 (es) 2003-10-31 2016-01-14 Takeda Pharmaceutical Company Limited Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
JP5179363B2 (ja) 2005-12-22 2013-04-10 武田薬品工業株式会社 固形製剤
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
PL2868315T3 (pl) 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CN107320732B (zh) * 2008-12-04 2021-09-07 于崇曦 高穿透性组合物及其应用
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
ES2525748T3 (es) * 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
US9241952B2 (en) 2010-05-24 2016-01-26 Ozstar Therapeutics Pty Ltd Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
KR102584819B1 (ko) 2011-01-19 2023-10-05 프랙틸 헬쓰, 인코포레이티드 조직의 치료를 위한 장치 및 방법
AU2012343332B2 (en) 2011-11-23 2017-03-16 Ozstar Therapeutics Pty Ltd Improved synergistic anti-diabetic compositions
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
WO2015077571A1 (en) 2013-11-22 2015-05-28 Fractyl Laboratories, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
IL296643B2 (en) 2012-02-27 2025-03-01 Fractyl Health Inc Hot ablation systems, devices and methods for tissue treatment
WO2013159066A1 (en) 2012-04-19 2013-10-24 Fractyl Laboratories, Inc. Tissue expansion devices, system and methods
EP3714826A1 (en) 2012-07-30 2020-09-30 Fractyl Laboratories, Inc. Electrical energy ablation systems and devices for the treatment of tissue
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
EP3169260B1 (en) 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
US12403138B2 (en) * 2019-11-22 2025-09-02 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021146535A1 (en) 2020-01-15 2021-07-22 Fractyl Laboratories, Inc. Automated tissue treatment devices, systems, and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
EP0957923A1 (en) 1999-11-24
JP2001512478A (ja) 2001-08-21
CA2272478A1 (en) 1998-08-27
AR011829A1 (es) 2000-09-13
US5859037A (en) 1999-01-12
BR9714505A (pt) 2000-03-21
CN1244801A (zh) 2000-02-16
AU741215B2 (en) 2001-11-29
HN1997000167A (es) 1999-02-09
EE9900345A (et) 2000-02-15
PE74399A1 (es) 1999-08-20
IS5058A (is) 1999-05-27
BG103671A (en) 2000-04-28
US5972973A (en) 1999-10-26
ZA981343B (en) 1998-11-16
UY24893A1 (es) 1998-07-10
IL130027A (en) 2005-09-25
KR20000071179A (ko) 2000-11-25
HUP0001528A3 (en) 2000-12-28
SK111899A3 (en) 2000-09-12
TR199902033T2 (xx) 2000-02-21
EA199900725A1 (ru) 2000-04-24
PL335166A1 (en) 2000-04-10
CZ289299A3 (cs) 1999-11-17
SV1998000010A (es) 1999-02-02
AU5590898A (en) 1998-09-09
NO993982D0 (no) 1999-08-18
NZ336002A (en) 2002-03-28
WO1998036755A1 (en) 1998-08-27
PA8447401A1 (es) 2001-12-14
IL130027A0 (en) 2000-02-29
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28

Similar Documents

Publication Publication Date Title
NO993982L (no) Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
IS5478A (is) Efnasambönd
IS5477A (is) Efnasambönd
ID22850A (id) Senyawa-senyawa pirazina
NO994877D0 (no) Kalsilytiske forbindelser
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
IS5208A (is) Efnasambönd
ID23497A (id) Kombinasi pembungkus-deterjen
ATE268553T1 (de) Fungizide zusammensetzung
IS5237A (is) Efnasambönd
IS5323A (is) Efnasambönd
IT246279Y1 (it) Guarnitura per mobili
ID22983A (id) Senyawa-senyawa fluorometoksimino
NO995007D0 (no) Forbindelser
FR2766075B1 (fr) Combine fourchette-cuillere
ES1038112Y (es) Archivador-encuadernador perfeccionado.
DE69737634D1 (de) Insektizide oxadiazinverbindungen
ES1036758Y (es) Rubela perfeccionada.
IT242776Y1 (it) Portaritratti perfezionato
ES1037470Y (es) Quevedos perfeccionados.
ES1038831Y (es) Carta-sobre perfeccionado.
ES1038633Y (es) Cotilo perfeccionado.
ES1038682Y (es) Caja-envase perfeccionada.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application